Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 425Neoplasms 284Carcinoma, Non-Small-Cell Lung 274Colorectal Neoplasms 236Prostatic Neoplasms 173Lung Neoplasms 171Carcinoma, Hepatocellular 157Stomach Neoplasms 126Leukemia, Myeloid, Acute 120Pancreatic Neoplasms 118Multiple Myeloma 106Recurrence 100Uterine Cervical Neoplasms 97Squamous Cell Carcinoma of Head and Neck 89Neoplasm Metastasis 88Rectal Neoplasms 87Ovarian Neoplasms 81Triple Negative Breast Neoplasms 78Small Cell Lung Carcinoma 72Head and Neck Neoplasms 70Brain Neoplasms 70Glioblastoma 65Esophageal Neoplasms 65Endometrial Neoplasms 59Colonic Neoplasms 59Melanoma 56Hematologic Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Motor Activity 48Glioma 48

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Advanced Hepatocellular Carcinoma (HCC) × Clear all
NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Not yet recruiting
116 enrolled
Gastrointestinal

Advanced Hepatocellular Carcinoma (HCC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡